⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13202339 | 0.84 | KDM4E (0.61) | — | |
| SCHEMBL12265346 | 0.84 | KDM4E (0.61) | — | |
| SCHEMBL13123499 | 0.80 | — | — | |
| SCHEMBL465815 | 0.79 | TGFBR1 (0.32) | — | |
| SCHEMBL17373914 | 0.79 | — | — | |
| SCHEMBL400287 | 0.76 | — | — | |
| SCHEMBL955457 | 0.73 | — | — | |
| SCHEMBL15083651 | 0.73 | — | — | |
| SCHEMBL1338814 | 0.72 | TDP1 (0.50) | — | |
| SCHEMBL33728 | 0.72 | TSHR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3040333-A1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | Novartis AG (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-9359326-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| CN-104987321-A | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG | 2015-10-21 | — | — | CN | disclosed |
| CN-104945373-A | Manufacturing process for pyrimidine derivatives | NOVARTIS AG | 2015-09-30 | — | — | CN | disclosed |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1575940-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004062601-A2 | ANTIBACTERIAL AGENTS | CHIRON CORPORATION (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |